Disclosed are compounds which are inhibitors of metalloproteases and which
are effective in treating conditions characterized by excess activity of
these enzymes. In particular, the compounds have a structure according to
the following Formula (I):
##STR1##
where R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, G and Z have
the meanings described in the specification. This invention also includes
optical isomers, diastereomers and enantiomers of Formula I, and
pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and
imides thereof. Also described are pharmaceutical compositions comprising
these compounds, and methods of treating metalloprotease-related maladies
using the compounds or the pharmaceutical compositions.
